Silverback therapeutics seattle Activator#
Silverback therapeutics seattle registration#
Silverback therapeutics seattle zip#

Silverback therapeutics seattle registration#

To preserve cash ahead of the ARS merger, Silverlake expects to reduce its remaining workforce by about 50 employees by early September. Silverback Therapeutics (SBTX) aims to raise 125 million from the sale of its common stock in an IPO, according to an amended registration statement. In March, it cut about 24 jobs as the result of a corporate restructuring. Silverback had 90 full-time workers at year end, according to its annual report. American Association for Cancer Research. Print ISSN: 0008-5472 ©2021 American Association for Cancer Research.

Silverback therapeutics seattle zip#

Seattle, Washington 98109 (206) 456-2900 (Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices) Laura. Author & Article Information Online ISSN: 1538-7445. (Exact name of registrant as specified in its charter) Delaware 2834 81-1489190 (State or other jurisdiction of. The board of directors would include three members designated by Silverback and seven directors from ARS. Search for other works by this author on: This Site. Under terms of the all-stock merger, shareholders of Silverback will own 37 percent of the combined company. Announcing its 4Q 2021 results, the clinical-stage biotech, Silverback Therapeutics (SBTX) announced on Thursday that the company decided to discontinue its SBT6050 and SBT6290. I believe we have found the optimal partner to provide value for our stockholders.” “ARS is an exciting late-stage company with compelling clinical data demonstrated with neffy, a path to near-term commercialization in a large and dissatisfied market and an expert team with proven experience in launching and commercializing market-leading nasal spray products such as Narcan. Back in Seattle training another new team on the Gator Bio system. “This transaction represents the result of a thorough and thoughtful strategic review process by Silverback,” said Chief Executive Laura Shawver in a statement. Silverback Therapeutics Jul 2016 - Dec 2018 2 years 6 months. Silverback’s shares closed down 11 percent on Friday at $3.91 on the Nasdaq exchange. Prior to that, it raised more than $200 million in venture capital, according to news reports. Silverback went public in December 2020 at $21 per share, which added roughly $242 million in cash to its balance sheet.

It expects to trade under the ticker symbol SPRY on the Nasdaq exchange. “Our initial goal is to first convert a significant portion of the existing 3.3 million people with injection devices today into neffy users.”ĪRS is a venture capital-backed firm, having raised at least $63 million according to regulatory filings. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023ĪRS Pharmaceuticals Says US Food and Drug Administration Schedules Type A Meeting on Allergy Spray for End of OctoberĪRS Pharmaceuticals to Meet With FDA on Neffy RejectionĪrs Pharmaceuticals, Inc.“We know there are 25 million people with serious Type 1 allergies who may benefit from having epinephrine medication,” said Lowenthal in a conference call. Connect Jennifer More, PHR Director, Human Resources. Wedbush Raises ARS Pharmaceuticals' PT to $13 From $5, Says Market Opportunity Intact Maintains Outperform RatingĪRS Pharmaceuticals, Inc. Senior Research Associate II at Silverback Therapeutics Seattle, WA. To learn more, visit View source version on : Silverback Therapeutics is located in Seattle, Washington.

Silverback therapeutics seattle Activator#

Initially, Silverback is creating a new class of targeted immuno-oncology agents that direct a TLR8 agonist myeloid cell activator to the tumor microenvironment in solid tumors to promote cancer cell killing.

What is Silverback Therapeuticss latest funding round Silverback. Silverback’s platform enables the strategic pairing of proprietary payloads that modulate key disease modifying pathways with monoclonal antibodies directed at specific disease sites. Silverback Therapeuticss headquarters is located at 500 Fairview Ave N, Seattle. is a clinical-stage biopharmaceutical company focused on leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered and tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases. Laura Shawver, Ph.D., Silverback’s Chief Executive Officer, and Valerie Odegard, Ph.D., Silverback’s President and Chief Scientific Officer, will provide a corporate overview which will be available on Silverback’s Investor Relations website beginning on Monday, January 10, 2022, at 7:00 AM ET (4:00 AM PT). Wainwright Bioconnect Conference from January 10-13, 2022. (Nasdaq: SBTX) (“Silverback”), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases, today announced that Silverback management will participate in the H.C.